Treatment of neuroblastoma with metaiodobenzylguanidine: results and side effects

Journal Article · Thu Jan 01 00:00:00 EST 1987 · Med. Pediatr. Oncol.; (United States)

DOI:https://doi.org/10.1002/mpo.2950150412· OSTI ID:5625496

Treuner, J; Klingebiel, T; Bruchelt, G; Feine, U; Niethammer, D

Between April 1984 and December 1985 we treated ten children suffering from neuroblastoma in a total of 25 metaiodobenzylguanidine (MIBG) courses. Five had had a relapse of neuroblastoma stage III or IV, three had never achieved a remission in spite of intensive chemotherapy, and two were treated with an unstable remission. The children were each administered from 1 to 5 courses with a dosage per course of between 1295 and 9065 MBq. The sum of the single doses during the whole course of therapy ranged between 3145 and 21,904 MBq per child. Five of five children suffering from bone pain and fever became free of complaints during the first three treatment days. Six of eight children with manifest tumor at onset of therapy responded well to the treatment: response extended from transitory decrease in elevated catecholamine levels in serum and urine to complete disappearance of large abdominal tumor masses. We also observed a decrease in bone marrow involvement and a stabilization of osteolytic lesions. Seven of these eight children died in spite of a good response from 55 to 350 days after the first MIBG treatment course. The only side effect we witnessed was a reversible bone marrow depression. In three children we combined the MIBG therapy with bone marrow transplantation.

• Research Organization: University Hospital, Tuebingen, Germany, F.R.
• OSTI ID: 5625496
• Journal Information: Med. Pediatr. Oncol.; (United States), Vol. 15:4
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
NEOPLASMS
RADIOTHERAPY
RADIOPHARMACEUTICALS
THERAPEUTIC USES
SIDE EFFECTS
ABDOMEN
BONE MARROW
CATECHOLAMINES
CHILDREN
PAIN
AGE GROUPS
AMINES
ANIMAL TISSUES
AROMATICS
BODY
BODY AREAS
DISEASES
DRUGS
HEMATOPOIETIC SYSTEM
HYDROXY COMPOUNDS
LABELLED COMPOUNDS
MEDICINE
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANS
PHENOLS
POLYPHENOLS
RADIOLOGY
SYMPTOMS
THERAPY
TISSUES
USES
550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)
560151 - Radiation Effects on Animals- Man